ALLGENESIS BIOTHERAPEUTICS INC.
Update：2025/12/03
Industries
Main Industry
Biotechnology
Main Product/Service
Allgenesis focuses on developing innovative ophthalmic therapies targeting both retinal and anterior segment diseases. Its pipeline includes AG-73305, a dual-action anti-VEGF and disintegrin molecule for diabetic macular edema and age-related macular degeneration; AG-80308, an FPR agonist for dry eye and ocular inflammation; and AG-86893, a tyrosine kinase inhibitor for pterygium. These programs aim to address unmet medical needs through novel mechanisms and advanced drug delivery approaches.
Founded Year
2014
Unified Business No.
54681545
Status
Active
Number of Employees
0
Total Paid-in
Capital
912,600,000 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Allgenesis is a privately owned, clinical stage, biopharmaceutical company situated in Taipei City, Taiwan.We strive to find solutions for major diseases of the eye affecting the vision of millions of people worldwide.Our mission is to establish a world-renowned biopharmaceutical business in Taiwan to invent and develop novel medicines for the global market.
